b-Endorphin is an opioid peptide cleaved from the precursor pro-hormone pro-opiomelanocortin, from which other peptides such as adrenocorticotropic hormone, b-lipotropic hormone, and a-melanocytestimulating hormone are also derived. a-Melanocytestimulating hormone and adrenocorticotropic hormone are well documented to regulate human skin pigmentation via action at the melanocortin-1 receptor. Whereas plasma b-endorphin is reported to increase after exposure to ultraviolet radiation, to date a functional role for b-endorphin in the regulation of human epidermal melanocyte biology has not been demonstrated. This study was designed to examine the involvement of the b-endorphin/l-opiate receptor system in human epidermal melanocytes. To address this question we employed reverse transcription^polymerase chain reaction, and immunohistochemistry/cytochemistry and immunoelectron microscopy using b-endorphin and l-opiate receptor speci¢c antibodies. A functional role for b-endorphin was assessed in epidermal melanocyte cultures by direct stimulation with the peptide. This study demonstrated the expression of l-opiate receptor mRNA in cultured epidermal melanocytes, as well as mRNA for pro-opiomelanocortin. In addition, we have shown that b-endorphin and l-opiate receptor are expressed at the protein level in situ in glycoprotein100-positive melanocytes. The expression of both b-endorphin and l-opiate receptor correlated positively with their di¡erentiation status in vitro. Furthermore, immunoelectron microscopy studies revealed an association of b-endorphin with melanosomes. Functional studies showed that b-endorphin has potent melanogenic, mitogenic, and dendritogenic e¡ects in cultured epidermal melanocytes deprived of any exogenous supply of pro-opiomelanocortin peptides. Thus, we report that human epidermal melanocytes express a fully functioning bendorphin/l-opiate receptor system. In the absence of any data showing cross-talk between the l-opiate receptor and the melanocortin-1 receptor, we conclude that the b-endorphin/l-opiate receptor system participates in the regulation of skin pigmentation.
b-Endorphin is an opioid peptide cleaved from the precursor pro-hormone pro-opiomelanocortin, from which other peptides such as adrenocorticotropic hormone, b-lipotropic hormone, and a-melanocytestimulating hormone are also derived. a-Melanocytestimulating hormone and adrenocorticotropic hormone are well documented to regulate human skin pigmentation via action at the melanocortin-1 receptor. Whereas plasma b-endorphin is reported to increase after exposure to ultraviolet radiation, to date a functional role for b-endorphin in the regulation of human epidermal melanocyte biology has not been demonstrated. This study was designed to examine the involvement of the b-endorphin/l-opiate receptor system in human epidermal melanocytes. To address this question we employed reverse transcription^polymerase chain reaction, and immunohistochemistry/cytochemistry and immunoelectron microscopy using b-endorphin and l-opiate receptor speci¢c antibodies. A functional role for b-endorphin was assessed in epidermal melanocyte cultures by direct stimulation with the peptide. This study demonstrated the expression of l-opiate receptor mRNA in cultured epidermal melanocytes, as well as mRNA for pro-opiomelanocortin. In addition, we have shown that b-endorphin and l-opiate receptor are expressed at the protein level in situ in glycoprotein100-positive melanocytes. The expression of both b-endorphin and l-opiate receptor correlated positively with their di¡erentiation status in vitro. Furthermore, immunoelectron microscopy studies revealed an association of b-endorphin with melanosomes. Functional studies showed that b-endorphin has potent melanogenic, mitogenic, and dendritogenic e¡ects in cultured epidermal melanocytes deprived of any exogenous supply of pro-opiomelanocortin peptides. Thus, we report that human epidermal melanocytes express a fully functioning bendorphin/l-opiate receptor system. In the absence of any data showing cross-talk between the l-opiate receptor and the melanocortin-1 receptor, we conclude that the b-endorphin/l-opiate receptor system participates in the regulation of skin pigmentation. Key words: l-opiate receptor/dendricity/melanogenesis/proopiomelanocortin/ skin. J Invest Dermatol 120: 1073^1080, 2003 b-Endorphin (b-END) is a cleavage product of the precursor pro-hormone pro-opiomelanocortin (POMC). Other peptides, including adrenocorticotropic hormone (ACTH), a-melanocytestimulating hormone (a-MSH), and b-lipotropic hormone (b-LPH) are also produced from POMC by the actions of the pro-hormone convertases 1 and 2 (Benjannet et al, 1991; Seidah et al, 1994) . It is now well established that the skin is also a local source and target for POMC-derived peptides (Thody et al, 1983; Slominski et al, 1993; . a-MSH and ACTH have been well documented to regulate human skin pigmentation via action at the melanocortin-1 receptor (MC-1R) (Lerner and McGuire, 1964; Hunt et al, 1994a, b, c; Suzuki et al, 1996; Wakamatsu et al, 1997) .
b-END is an opioid peptide representing the 61^91 amino acid sequence of b-LPH (Dalayeun et al, 1993) . Opioids exert their biologic e¡ects by activating membrane-bound receptors, which consist of three major classes mu (m), delta (d), and kappa (k) (Pasternak, 1993) . b-END binds with high a⁄nity to m and d opiate receptors (Gilmore and Weiner, 1989) . b-END and other opioids, such as the enkephalins and dynorphins, mediate their biologic actions by inhibition of the adenylate cyclase pathway and a decrease in the formation of intracellular cyclic adenosine monophosphate (Kie¡er, 1995) .
Elevated plasma b-END levels have been reported in dermatoses, including psoriasis (Glinski et al, 1994) , atopic dermatitis (Glinski et al, 1995) , and the pigmentation disorder vitiligo (Mozzanica et al, 1992; Caixia et al, 2001) . The onset of these conditions can be triggered or their course can be aggravated by psychologic stress (Seville, 1989) , thus implicating the involvement of classical stress hormones such as the endorphins in these disorders. Moreover, increased plasma b-END and b-LPH levels post-ultraviolet (UV)A exposure have been associated with the observed increase in skin pigmentation in humans (Levins et al, 1983) ; however, more recent studies have reported that plasma b-END levels do not rise after single or repeated exposure to UVA, UVA-1, or UVB radiation (Wintzen et al, 2001) .
ACTH, a-MSH (Schauer et al, 1994) , and b-END are produced by human epidermal keratinocytes (EK) in vitro and their production is upregulated in response to UVB radiation. In addition, the presence of b-END, a-MSH, andACTH has also been identi¢ed in normal and malignant human melanocytes in vitro (Slominski, 1998) , as well as in human skin (Slominski et al, 2000b) . The expression of b-END and other POMC peptides has been demonstrated in normal and pathologic skin, and was elevated under pathologic conditions but also during healing and regeneration (Slominski et al, 1993; Nagahama et al, 1998) .
Recent data indicate that the human epidermis expresses a functionally active b-END receptor. Both m-opiate receptor mRNA and protein expression have been found in human epidermis (Bigliardi et al, 1998) . b-END is a speci¢c agonist at the m-opiate receptor in human skin; receptor expression was downregulated by b-END and this was reversed with an anti-m-opiate receptor antibody or the antagonist naloxone. Notably, b-END was also shown to upregulate the expression of cytokeratin 16, a marker for keratinocyte di¡erentiation (Bigliardi-Qi et al, 2000) .
Whereas a-MSH and ACTH has been shown to regulate human skin pigmentation (Lerner and McGuire, 1964; Hunt et al, 1994a, b, c; Suzuki et al, 1996; Wakamatsu et al, 1997) . These studies have led to an MC-1R-centric view of the regulation of mammalian melanogenesis; however, b-LPH, the immediate precursor of b-END, stimulates melanogenesis in amphibians and in sheep (Lohmar and Li, 1968) . Moreover, elevated serum levels of b-LPH have been associated with generalized hyperpigmentation in humans (Al Rustom et al, 1986) . Despite these tentative clues, however, a functional role for b-END in the regulation of human skin pigmentation has not yet been demonstrated.
This study examines the b-END/m-opiate receptor system in epidermal melanocyte (EM) biology and presents evidence that b-END is a potent melanocyte modi¢er by upregulating melanocyte proliferation, dendricity, and melanogenesis.
MATERIALS AND METHODS

Cell culture
EM EM cultures were established from normal human haired scalp tissue, obtained with informed consent after elective plastic surgery, from eight females (age range 43^62 y, mean age 52 y, photo skin type III^V, Fitzpatrick classi¢cation; Fitzpatrick et al, 1974) . This study was conducted with Local Human Ethics Committee approval. All cell culture reagents were obtained from Invitrogen Ltd (Paisley, U.K.) unless otherwise stated. The skin samples were collected in RPMI 1640 medium supplemented with 10% fetal bovine serum, 12.5 mg fungizone per ml, 500 units per ml penicillin, and 500 mg streptomycin per ml, and were processed within 5 h of surgery.
Brie£y, tissue specimens were washed with 0.1 M phosphate-bu¡ered saline (PBS) pH 7.4 containing 12.5 mg fungizone per ml, 500 units per ml penicillin, and 500 mg streptomycin per ml. Epidermal sheets were separated from the underlying dermis after an 18 h incubation in 0.25% trypsin solution at 41C and placed in T25 cell culture £asks (Corning Costar Corporation, Cambridge, MA) containing Eagle's minimal essential medium (EMEM) supplemented 2% FBS, 1 Â concentrated nonessential amino acid mixture, antibiotics, 2 mM L-glutamine, 5 ng basic ¢broblast growth factor per ml, and 5 ng endothelin-1 per ml (Sigma, Poole, Dorset, U.K.). Residual epidermal material was carefully removed and the medium was replenished after 48 h. Cells were incubated at 371C in a 5% CO 2 atmosphere and fed every third day. EK These were established by selectively trypsinizing EM from the coculture at the primary culture stage, using 0.05% trypsin and 0.53 mM ethylenediamine tetraacetic acid solution. The detached EM were transferred into a separate culture dish, the remaining EK were then switched to keratinocyte serum free medium.
Isolation of RNA EM and EK were maintained in culture media without FBS or bovine pituitary extract (BPE) 48 h prior to all experiments. This treatment removes all exogenous sources of POMC peptides, as the half-lives of a-MSH, ACTH (Eberle, 1988) , and b-END (Morch and Pedersen, 1995) are less than 60 min. Total RNA was isolated from detached EM and EK by the guanidinium thiocyanate^phenolĉ hloroform-based method, using Tri-Reagentt (Sigma, Dorset, U.K.) according to the manufacturer's instructions. Total RNA was isolated from the aqueous phase and the resulting RNA pellet was dissolved in nuclease-free water (Sigma, Dorset, U.K.). Total RNA isolated from EM was then puri¢ed using a Dynabeads mRNA direct kit (Dynal AS, Oslo, Norway) according to the manufacturer's instructions. This additional puri¢cation step was necessary to remove traces of melanin, which can be inhibitory to the polymerase chain reaction (PCR). (Eckhart et al, 2000) . To avoid possible contamination of genomic DNA, extracted total RNA samples were additionally treated with deoxyribonuclease I, ampli¢cation grade (Invitrogen Ltd) according to the manufacturer's instructions.
Reverse transcriptase^PCR The synthesis of cDNA was performed using RevertAid TM M-MuLV Reverse Transcriptase (MBI Fermentas, Vilnius, Lithuania) according to the manufacturer's instructions using 2 mg of total RNA or 0.2 mg of mRNA and oligo(dT) 18 and random hexamer primers (Sigma Genosys, Pampisford, Cambridgeshire, U.K.). All PCR reagents were obtained from MBI Fermentas, unless otherwise stated.
One microliter of cDNA was used in the PCR ampli¢cation in a 50 ml reaction mixture containing the following components: 1 ÂPCR bu¡er [75 mM Tris^HCl pH 8.8, 20 mM (NH 4 ) 2 SO 4 , 0.01% Tween 20], 1.0 or 2.5 mM MgCl 2 for POMC and m-opiate receptor-speci¢c primers, respectively, 20 pmol of each primer (Sigma Genosys), 0.2 mM deoxyribonucleoside triphosphate mix, 1.0 unit of Taq DNA polymerase, and, ¢nally, nuclease-free water (Sigma, Dorset, U.K.) was added to make a ¢nal reaction volume of 50 ml. POMC was ampli¢ed using primer sets as previously described by Slominski et al (1995) and a modi¢ed protocol with one cycle at 941C for 5 min, 35 cycles at 941C for 1 min, 671C for 1 min, 721C for 1 min, and a ¢nal cycle at 941C for 1 min, 671C for 1 min, 721C for 10 min. Plasmid containing POMC gene (gift from Dr J. Ancans, University of Riga, Latvia) was used as a positive control for POMC mRNA expression. m-Opiate receptor was ampli¢ed using primers sets and PCR parameters as described by Bigliardi et al (1998) . EK were used as a positive control cell line for m-opiate receptor mRNA expression. RNA samples that were not reverse transcribed and the omission of cDNA from the reaction mixture served as negative controls.
Ampli¢cations were performed using the Hybaid PCR sprint temperature cycling system (Hybaid, Ashford, Middlesex, U.K.). After ampli¢cation, 10 ml of the reaction mixture was mixed with 4 ml gel loading solution (MBI Fermentas) and loaded directly on to 1.5% agarose gel (Sigma, Dorset, UK) containing 1 mg per ml of ethidium bromide (Sigma, Dorset, UK). A 100 bp DNA ladder (New England Biolabs, Hitchin, Hertfordshire, U.K.) was also loaded followed by electrophoresis at a constant voltage of 100 V using 0.5 Â Tris-borate bu¡er. Gels were photo-documented using the UVitec gel documentation system (UVitec Limited, Cambridge, U.K.).
Immunohistochemistry Normal human haired scalp tissue was obtained after elective plastic surgery (from ¢ve females, age range 43^60 y, mean age 50 y) or from occipital scalp tissue of two normal healthy males (age 23 and 36 y). The tissue was cut into approximately 0.4 cm 2 segments and was mounted using OCTt embedding medium (Raymond A. Lamb, Eastbourne, East Sussex, U.K.). Seven micrometer thick cryosections were cut on to poly L-lysine coated slides. The slides were air-dried at room temperature for 1 h and then ¢xed in ice cold acetone for 10 min at À201C and subsequently rehydrated in PBS for 5 min.
Sections were blocked in 10% normal donkey serum in PBS for 90 min at room temperature and then rinsed brie£y in PBS. This was followed by incubation with the ¢rst primary monoclonal antibody b-END 1 : 10 (Biogenesis, Poole, Dorset, UK) or m-opiate receptor 1 : 100 (Gramsch Laboratories, Schwabhausen, Germany) in 1% normal donkey serum in PBS at 41C for 18 h. After incubation the antibodies were carefully aspirated and the sections were washed four times in PBS for 20 min followed by a ¢nal rinse in distilled water. The sections were then incubated with a rhodamine-conjugated donkey anti-rabbit or anti-mouse secondary antibody (Jackson Immunoresearch Laboratories, Inc., West Grave, Pennsylvania, USA). The secondary antibodies were used at a 1 : 50 dilution and incubated for 60 min at room temperature, followed by four washes in PBS. For the detection of the second marker the sections were further blocked with 10% normal donkey serum, covered and incubated for 90 min at room temperature. After a brief rinse in PBS they were incubated with the second primary antibody, NKI/beteb 1 : 30 (Monosan, Uden, the Netherlands), a melanocyte lineage-speci¢c marker against glycoprotein100 for 2 h at room temperature, followed by subsequent washing steps.
The sections were then incubated with a £uorescein-conjugated donkey anti-mouse secondary antibody (Jackson Immunoresearch Laboratories, Inc.) for 60 min at room temperature. The sections were washed in PBS as previously described, rinsed in distilled water, carefully blotted dry and then mounted in Vectashield mounting medium with 4 0 ,6 -diamidino-2-phenylindole (Vector Laboratories Ltd, Peterborough, U.K.). The omission of both primary antibodies, but the inclusion of secondary antibodies, served as negative controls.
The resulting staining was visualized with a Leica DMIRB/E £uorescence microscope (Leica,Wetzlar, Ossett, Germany) and photo-documented with the aid of a computer assisted 3 -CCD color video camera (Optivision, Ossett, West Yorkshire, U.K.) and the Image Grabber PCI graphics program (Neotech Ltd, Easleeigh, Hampshire, U.K.). The images produced with the two di¡erent £uorochromes rhodamine (red) and £uorescein (green) were subsequently merged together using the Paint Shop Prot 7 graphics program (JascSoftware, Banbury, Oxon, U.K.). Co-localization of b-END and m-opiate receptor with gp100-positive EM was indicated by the production of a yellow color.
Immunocytochemistry For staining of cultured EM and EK (passages 2^5), cells were seeded into eight-well Laboratory-Tek s chamber slides (ICN Biomedicals, Inc., Aurora, OH, USA) at a seeding density of 5000 cells per well and were grown for at least of 2^3 d. FBS and BPE were omitted from the culture media 48 h prior to immunostaining. Cells were rinsed brie£y in PBS for 5 min and then ¢xed in ice cold methanol for 10 min at^201C and subsequently rehydrated in PBS for 5 min. Brie£y, cells were blocked in 10% normal goat serum for 90 min at room temperature, rinsed brie£y in PBS and incubated with either b-END 1 : 10 or m-opiate receptor 1 : 100 antibodies in 1% normal goat serum in PBS at 41C for 18 h. Subsequent steps in immunostaining were performed using the DAKO LSAB s 2 HRP kit and DAKO AEC substrate system (DAKO, Carpinteria, CA) according to the manufacturer's instructions.
Assessment of melanin content, dendricity, and cell proliferation EM (passages 2^5) were seeded at a density of 1 Â 10 5 cells per T25 cell culture £ask (Corning Costar Corporation, Cambridge, MA) and allowed to attach overnight. Melanocyte cultures were grown without FBS and BPE for 48 h prior to stimulation with 10^8 M b-END (Sigma, Dorset, U.K.) for 72 h. Melanocytes from the same donor were maintained in parallel in the absence of the peptide and served as a negative control. b-END (10^8 M) was chosen for stimulation, as the greatest e¡ects on melanogenesis, dendricity, and proliferation were seen at this concentration during preliminary experiments compared with 10^6 M and 10^1 0 M. The testing of a broader range of b-END concentrations was di⁄cult given the limitations of melanocyte number at low passage.
For the assessment of melanocyte dendricity, cells were photographed 24 and 72 h after b-END stimulation. Representative photographs were taken from seven to eight random and di¡erent ¢elds incorporating approximately 10 cells for each cell line. Changes in EM dendricity were assessed and compared with controls. The cells were subsequently trypsinized and counted using a Neubauer counting chamber. Melanocytes were then pelleted by centrifugation and solubilized in up 0.5 ml of 1 M sodium hydroxide, followed by boiling for 10 min. Melanin content was measured spectrophotometrically at 475 nm. A standard curve of synthetic melanin (Sigma, Dorset, U.K.) 0.05^100 mg per ml was used as a basis for the determination of melanin content. Results were determined as picograms of melanin per cell and expressed as percentage increase in melanin content above control unstimulated cells. The increase in cell number was expressed as percentage increase in cell number above control unstimulated levels.
Immunogold transmission electron microscopy EM were established from normal human scalp tissue. FBS and BPE were removed from the culture medium 48 h prior to experiments. Melanocyte cultures (passages 3^5) were processed for immunoelectron microscopy as follows: cells were trypsinized and then pelleted by gentle centrifugation. Cells were subsequently ¢xed in 0.5% glutaraldehyde (Agar Scienti¢c, Stanstead, Essex, U.K.) and 2% paraformaldehyde (Sigma, Dorset, U.K.) in 0.1 M sodium cacodylate bu¡er (Sigma, Dorset, U.K.) containing 0.027 mM CaCl 2 (Sigma, Dorset, U.K.) bu¡ered to pH 7.4 for 1 h at room temperature. After ¢xation cells were washed in PBS over 25 min, rinsed in 0.1 M glycine (Sigma, Dorset, U.K.) in PBS for 5 min and then pelleted through 1% low melting point agarose (Bio-Rad Laboratories, Hercules, CA) in PBS. The cell/agar blocks were dehydrated in graded series of ethanol. Blocks were in¢ltrated with hydrophillic Unicryl resin (British BioCell International, Cardi¡, Wales, U.K.) followed by polymerization using UV light (360 nm) of 2 Â 8 W for 3 d at 41C.
Ultrathin sections (90 nm) were cut using a Reichert-Jung ultramicrotome (Vienna, Austria), mounted on 200 mesh nickel grids coated with a carbon ¢lm (Agar Scienti¢c) and blocked in 10% normal goat serum and 2% bovine serum albumin in PBS (pH 8.2) for 1 h. One percent normal goat serum in the above blocking bu¡er was used to dilute both the primary and secondary antibodies. The sections were then washed twice in PBS containing 2% bovine serum albumin (pH 8.2) followed by incubation with the primary antibodies b-END neat or m-opiate receptor 1 : 100 for 18 h at 41C. The sections were then washed in 2% bovine serum albumin in PBS, and then incubated in 1 : 60 dilution of the secondary goat antirabbit or anti-mouse antibody conjugated to 10 nm gold particles (British BioCell
Sections were lightly counterstained with 2% uranyl acetate and Reynold's lead citrate solution, and examined and photographed using a JEM-1200 EX transmission electron microscope (Jeol Tokyo, Japan).
Statistical analysis Statistical signi¢cance was assessed using Student's paired t test.
RESULTS
EM express l-opiate receptor and POMC mRNA in vitro Reverse transcriptase^PCR with primers speci¢c for mopiate receptor produced ampli¢cation products of the expected size of 433 bp in normal human EK and EM ( Fig 1A) . As b-END is a cleavage product of POMC, the expression of the POMC message was also analyzed in cultured EK and EM and produced the expected 260 bp product speci¢c for exon 3 of the POMC mRNA (Fig 1B) . Ampli¢cation of RNA samples that were not reverse transcribed and samples where cDNA had been omitted from the reaction mixture were also subjected to PCR. These negative controls did not reveal a speci¢c product (Fig 1A, B) . Thus, cultured EM express the mRNA for both POMC and the m-opiate receptor.
EM express b-END and l-opiate receptor in situ The expression of b-END protein was present throughout the epidermis but was more prominent in di¡erentiated cells in the spinous and granular layers compared with undi¡erentiated basal cells. Individual dendritic cells in the basal layer of the epidermis showed strong cytoplasmic b-END expression (Fig 2A) . Double immunolabeling with antibodies against gp100 and b-END con¢rmed the melanocytic nature of these b-END-positive cells (Fig 2C) . The omission of both primary antibodies but inclusion of secondary antibodies did not produce any speci¢c staining (data not shown).
Cytoplasmic m-opiate receptor protein expression was observed throughout the epidermis but here was stronger in the basal layer of the epidermis (Fig 2D) . Double immunolabeling with m-opiate receptor and gp100 speci¢c antibodies revealed strong colocalization of m-opiate receptor with gp100-positive EM (Fig 2F) . To assess which cell subpopulations in the epidermis expressed both the m-opiate receptor and b-END, double immunolabeling was used. Co-localization of m-opiate receptor with b-END was prominent in the di¡erentiated cell layers and also in individual cells located in the basal layer of the epidermis. These cells showed an identical distribution pattern to the gp100-positive cells (Fig 3C) . Therefore, these results show Figure 1 . Detection of l-opiate receptor and POMC-speci¢c transcripts by reverse transcriptase^PCR in cultured EM and EK. Total RNA was isolated from cultured cells and ampli¢ed by reverse transcription using m-opiate receptor and POMC-speci¢c primers followed by 1.5% agarose gel electrophoresis. Detection of a 433 bp product speci¢c for mopiate receptor (A), detection of a 260 bp product speci¢c for POMC (B). that both b-END and m-opiate receptor colocalize with gp100-positive EM in situ.
EM and keratinocytes express l-opiate receptor and b-END in vitro Cultured EM exhibited a positive correlation between level of b-END expression and di¡erentiation status, more di¡er-entiated melanocytes (i.e., more dendritic and more pigmented) showed stronger b-END immunoreactivity compared with less di¡erentiated cells. Expression of b-END was present throughout the cell body but was prominent in granular structures in the perinuclear region of the cells and interestingly, also in the nucleus (Fig 4A) . Similarly, the expression of the m-opiate receptor was also correlated with di¡erentiation status. Immunoreactivity was observed throughout the cell body being strongest in more di¡erentiated melanocytes and showed a rather di¡use granular staining pattern. Strong expression was also seen on the cell membrane (Fig 4B) . The omission of the primary antibody did not result in any staining (Fig 4C) .
b-END was strongly expressed in the perinuclear region of cultured EK and was more marked in di¡erentiated keratinocytes (Fig 4D) . This result is in agreement with the in situ ¢ndings above, where strong immunoreactivity was observed in the suprabasal layers of the epidermis. In contrast to EM, granular staining was not observed in the EK nucleus. Immunoreactivity for m-opiate receptor was also expressed in cultured EK but in these cells was prominent in the perinuclear region of cells with a basal cell phenotype (Fig 4E) . No staining was observed in the negative control where the primary antibody had been omitted (Fig 4F) . Thus, these in vitro results show that both EM and EK express b-END and m-opiate receptor protein.
b-END upregulates dendricity in EM in vitro In order to assess the functional signi¢cance of m-opiate receptor and b-END protein expression in EM both in situ and in vitro, we determined the e¡ects of b-END stimulation on EM morphology. Prior to b-END stimulation EM exhibited a predominately bipolar morphology with occasional tripolar cells (Fig 5A,C) . Stimulation with b-END (10^8 M) induced cell dendricity in all EM lines examined (n ¼ 8). The e¡ect was variable, with some cultures more responsive than others. The extent of b-END stimulation of dendricity did not correlate with di¡erent photo skin types (Fig 5B,D) . Therefore, these results show that exogenous b-END can signi¢cantly increase dendricity in cultured EM.
b-END upregulates melanogenesis and proliferation in EM in vitro Next we examined the e¡ect of b-END on melanogenesis and proliferation. Stimulation of EM cultures derived from photo skin types III^V (Fitzpatrick classi¢cation) with b-END (10^8 M) signi¢cantly increased melanogenesis after 72 h in all cell lines tested (n ¼ 8; po0.001) (Fig 6A) . The e¡ects were variable in the cell lines examined and ranged from 13.2%73.14 (SEM) to 38.5%73.14 with an average increase of 23.6%73.14 above control unstimulated levels. Visible increases in melanogenesis were evident in stimulated cell pellets of cell lines that had low basal melanin levels ( Fig 6A1) compared with high basal melanin levels (Fig 6A2) . Figure 2 . Expression of b-END and l-opiate receptor in human skin EM. Normal human scalp cryosections (7 mm) were processed for double immunolabeling as described in Materials and Methods. Expression of b-END was present throughout the epidermis and was more prominent in di¡eren-tiated keratinocytes than in basal keratinocytes and was also marked in individual cells in the basal layer (A) (arrowheads). Identi¢cation of gp100-positive EM located in the basal layer of the epidermis (B). b-END strongly colocalized (yellow) with gp100-positive EM (C) (arrowheads). m-Opiate receptor expression was present throughout the epidermis and was stronger in the basal layer (D) (arrowheads). Identi¢cation of gp100-positive EM located in the basal layer of the epidermis (E). m-Opiate receptor strongly colocalized (yellow) with gp100-positive EM (F) (arrowheads). Original magni¢cation Â 400. Evaluation of cell proliferation showed a signi¢cant increase in EM number with b-END (10^8 M) stimulation after 72 h (po0.001) ( Fig 6B) ; however, the e¡ects of b-END on EM proliferation were also variable (n ¼ 8). The increase in cell number ranged from 8.5%72.39 (SEM) to 29.5%72.39 with an average increase of 14.9%72.39 above control unstimulated levels. Based on the above in vitro results we propose that b-END has signi¢cant melanogenic and mitogenic e¡ects on EM.
b-END and l-opiate receptor colocalize on/in melanosomes in cultured EM Lastly, we then addressed the issue of where b-END and m-opiate receptor are located in melanocytes using immunoelectron microscopy on cultured EM. Results revealed a close association of b-END with melanosomes. b-END labeling was con¢ned predominately, but not exclusively, to stage II and III melanosomes, which represent early stages of active melanogenesis (Fig 7A) . m-Opiate receptor labeling was also predominately present in premelanosomes but occasionally associated with mature melanosomes (Fig 7B) . Immunogold labeling of m-opiate receptor was also located on the cell membrane of melanocytes (data not shown). Thus, these results indicate a speci¢c association of b-END and its receptor on/in melanosomes in cultured EM.
DISCUSSION
Here we show for the ¢rst time that: (i) the b-END/m-opiate receptor system is prominently expressed in human EM in situ and Figure 4 . b-END and l-opiate receptor are expressed in cultured EM and EK. Cells were seeded into eight-well chamber slides and grown without FBS or BPE for 48 h prior to immunostaining. Cells were ¢xed in ice cold methanol, blocked in 10% normal goat serum, and then incubated with the primary antibodies against b-END and m-opiate receptor. Omission of the primary antibody served as a negative control. The expression of b-END (A) and m-opiate receptor (B) was variable in cultured EM, expression was higher in di¡erentiated cells compared with undi¡erentiated cells and was strongest in the perinuclear region of the cells (arrowheads). b-END immunoreactivity was also evident in granular structures in the nucleus (A) (arrow). Negative control from which the primary antibody was omitted (C). Immunoreactivity for b-END in EK correlated positively with their di¡erentiation status and was marked in more di¡erentiated keratinocytes than basal keratinocytes, stronger expression was con¢ned to the perinuclear region of the cell (D) (arrowheads). Expression of m-opiate receptor was variable in EK and was stronger in basal keratinocytes compared with more di¡erentiated keratinocytes (E) (arrowheads). Negative control from which the primary antibody was omitted (F). Original magni¢cation Â 150. in vitro; (ii) the peptide and receptor are associated closely with melanosomes; and (iii) the b-END/m-opiate receptor system is functionally active in the regulation of melanocyte biology via its ability upregulate melanocyte dendricity, proliferation, and pigmentation. These new data strongly suggest that we need to broaden our view of the regulation of human pigmentation from its current MC-1R-centric state.
A) Control
A role for several POMC peptides, especially a-MSH and ACTH, in the regulation of EM melanogenesis (Hunt et al, 1994a, b, c; Suzuki et al, 1996; Wakamatsu et al, 1997) and hair follicle pigmentation (Logan and Weatherhead, 1981; Burchill et al, 1986 Burchill et al, , 1989 Burchill et al, , 1993 via signaling through the MC-1R is well documented; however, a direct or even indirect role for b-END in pigmentation biology remains controversial. Tantalizing clues have been suggested, e.g., via the upregulation of b-END post-UV radiation (Levins et al, 1983) . We show here that the b-END/ m-opiate receptor system is fully expressed in human EM. Our detection of mRNA expression for POMC in cultured adult scalp EM and EK (Fig 1A) con¢rms recent work in neonatal foreskin epidermis Schiller et al, 2001) . Although b-END can signal through both the m-opiate receptor . A visible increase in melanogenesis was evident in pellets of the stimulated cells that contained low basal melanin levels (A1) and was not appreciable in cells containing high basal melanin levels (A2). For assessment of cell proliferation, cells were seeded at a density of 1 Â 10 5 and cell counts were determined before and after 72 h b-END stimulation. Results are expressed as a percentage increase in cell number over control unstimulated levels (mean 7 SEM of eight experiments). Statistical signi¢cance was assessed by Student's paired t test ( nnn po0.001) (B). Figure 7 . Ultrastructural localization of b-END and l-opiate receptor in/on melanosomes in cultured EM. Immunoelectron microscopy was performed on cultured EM using b-END and m-opiate receptor speci¢c antibodies labeled with secondary antibodies conjugated to 10 nm gold particles. Melanosomes at di¡erent stages of maturation (I^IV) can be seen by the increasing electron density of the organelles. b-END-labeled gold particles were associated primarily with the outer membrane of stage II and III melanosomes. The labeling was weaker in stage IV melanosomes (A) (arrowheads). The frames indicate the origins of inserts (Ai) and (Aii). m-Opiate receptor labeled gold particles were associated with premelanosomes and occasionally with mature melanosomes (B) (arrowheads). The frames indicate the origin of the inserts (Bi) and (Bii). No gold labeling was seen in the negative control incubated with the gold-conjugated secondary antibody only (C). Original magni¢cation Â 20,000. and d-opiate receptor (Gilmore and Weiner, 1989) , recent evidence suggests that b-END binds speci¢cally to the m-opiate receptor in EK (Bigliardi et al, 1998; Bigliardi-Qi et al, 2000) and these cells do not express mRNA for either d-opiate receptor and k-opiate receptor (Bigliardi et al, 1998) . Using EK as a positive control for m-opiate receptor expression, we demonstrated m-opiate receptor mRNA expression also in cultured adult scalp EM (Fig 1B) .
Reports on the expression of b-END at the protein level in normal human epidermis are controversial. Whereas Slominski et al (1993) showed b-END immunoreactivity in the basal layer of scalp epidermis and also in follicular keratinocytes, others have reported that b-END was expressed only in suprabasal keratinocytes of human epidermis (Nagahama et al, 1998) . Using a speci¢c anti-b-END monoclonal antibody, we report here b-END expression throughout the epidermis, but with increased immunoreactivity in the suprabasal layers; however, we also show high expression of b-END in gp100-positive EM (Fig 2C) . Examination of b-END expression was shown herein in normal human scalp specimens derived from individuals of photo skin type III^V (Fitzpatrick classi¢cation) . Whether b-END expression in human epidermis correlates with photo skin types is currently under investigation, and this may explain the di¡erences between our observations and the ¢ndings of others (Slominski et al, 1993; Nagahama et al, 1998) .
The expression of m-opiate receptor was recently reported throughout the epidermis with higher expression in the basal layer (Bigliardi et al, 1998) , but this study did not identify m-opiate receptor expression in basal melanocytes speci¢cally. m-Opiate receptor expression in EM was a prominent ¢nding in the current study (Fig 2F) . Thus, the presence of the b-END ligand and mopiate receptor system in both EM and EK provides the basis for both autocrine and paracrine mechanisms to regulate melanocyte behavior.
The novel and fundamental aspect of this study was its examination of a role for the b-END/m-opiate receptor system in the modulation of melanocyte biology. Unlike its fellow POMC peptides, a-MSH and ACTH, which stimulate melanogenesis, dendricity, and proliferation in human EM via the MC-1R (Hunt et al, 1994c; Abdel-Malek et al, 1995; Suzuki et al, 1996) , a regulatory role for b-END in EM biology has not hitherto been demonstrated. Clues that such a role does indeed exist derive from the observation that plasma b-END and b-LPH levels increase after exposure to UV radiation (Levins et al, 1983; Belon, 1985) , although it has also been suggested that b-END solely of keratinocyte origin may be implicated in UV-induced melanogenesis . In view of the present ¢ndings, we can now con¢dently propose that b-END of melanocyte origin may play a more pivotal role in these melanocyte-speci¢c functions.
Autocrine control of melanocyte function was evident from a positive correlation between b-END expression and melanocyte di¡erentiation status (i.e., pigmentation and dendricity) (Fig 4A) . These results suggest that not only is b-END expressed by cultured EM but it may also be involved in the modulation of melanocyte di¡erentiation. Given that the expression of the m-opiate receptor correlated positively with EM di¡erentiation (Fig 4B) , the level of m-opiate receptor expression may be upregulated by its ligand b-END, as occurs with the binding of a-MSH/MC-1R system .
Whereas the expression of the receptor and ligand is highly suggestive of a functional b-END/m-opiate receptor system in EM, direct evidence is only obtainable from functional studies. Thus, we also provide evidence that exogenously supplied b-END can stimulate increased melanogenesis and proliferation in EM cultures (Fig 6A,B) . Importantly, these increases are of a similar magnitude to those reported for a-MSH and ACTH stimulation of EM (Hunt et al, 1994b,c) , and so securely positions b-END as having melanocortin activity despite not signaling via MC-1R.
We have also demonstrated that b-END has potent dendritogenic e¡ects on EM. Thus, b-END-stimulated melanocytes produce more melanized pigment granules to facilitate more active transfer of this melanin to recipient keratinocytes. In addition, we have identi¢ed an association of b-END with melanosomes, this ¢nding concurs with the recent identi¢cation of the full POMC processing system in human melanosomes (Peters et al, 2000) and suggests that melanogenesis may be largely regulated locally within this secretory granule. This scenario may include the possibility of internalization of the receptor/ligand complex into the melanosome and in this way facilitate intramelanosomal regulation and subsequent melanogenesis.
A consistent, though confounding, feature of melanocortin research is the donor variability in melanocyte responsiveness. Similar to the situation with a-MSH and ACTH stimulation of EM cultures (Hunt et al, 1994c (Hunt et al, , 1996 , donor variability in b-END responsiveness was also a feature of our study. It is now appreciated that this interindividual variation for a-MSH and ACTH re£ects di¡erences in the extent of peptide binding to the MC-1R and its subsequent signaling activity. A similar situation is likely to pertain to the m-opiate receptor.
It is now well documented that a-MSH and ACTH, acting via the MC-1R, stimulates melanogenesis predominately by activating the adenylate cyclase/cyclic adenosine monophosphate second messenger system (Busca and Ballotti, 2000) . By contrast, b-END exerts its biologic actions via the inhibition of this signaling pathway. Protein kinase C-b dependent pathways, however, are increasingly being implicated in the regulation of melanogenesis (Park et al, 1993) . In support of this emerging view, it has been recently reported that topical application of bisindolylmaleimide, a selective protein kinase C inhibitor, reduces skin pigmentation in guinea pig skin in vivo.
1 Our data support this view, and we would like to propose that b-END/m-opiate receptor interaction may signal via the protein kinase C b-isoform causing direct activation of tyrosinase and stimulating melanogenesis. In this context, it has been proposed that activation of protein kinase C stimulates mouse tyrosinase promoter activity by a¡ecting the amount or function of microphthalmia-associated transcription factor expression (Mahalingam et al, 1997) . It is possible that b-END/m-opiate receptor signaling could operate on such systems at the level of gene transcription resulting in an increase in tyrosinase expression and consequently the upregulation of melanogenesis.
It will be important to determine whether b-END production by EM is upregulated in response to stress, e.g., UV radiation, pathology, etc. Indeed, patients with rheumatoid arthritis exhibit high levels of b-END in synovial £uid (Denko et al, 1986) . In light of our current observations, we would like to speculate that this local increase in b-END could also be responsible for the hyperpigmentation commonly observed in the skin of a¡ected joints in these patients (Gedalia et al, 1989) .
In conclusion, our ¢ndings propose an important new role for b-END in the regulation of human skin pigmentation. In contrast to the other melanocortins, this pigmentary response occurs via an MC-1R independent mechanism, and so forces us to broaden our current MC-1R-centric view of pigmentation control. Thus, these results should stimulate exciting new research avenues into the fundamentals of the regulation of skin pigmentation and o¡er insights into new therapies. It is also worth adding here that these new data contribute to the evidence that mammalian skin expresses a full range of regulatory elements of the hypothalamic^pituitary^adrenal axis (Slominski and Wortsman, 2000; Slominski et al, 2000a Slominski et al, , 2001 , and provides a further developmental strand to the newly emerging ¢eld of cutaneous neuroendocrinology.
